Can-Fite Biopharma FY19 Net Loss $9.5M vs $6.6M In FY18, Sales $2M vs $3.8M In FY18
Portfolio Pulse from Benzinga Newsdesk
Can-Fite Biopharma reported a net loss of $9.5 million for FY19, an increase from the $6.6 million loss in FY18. Sales also decreased to $2 million from $3.8 million in FY18.
March 27, 2020 | 11:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Can-Fite Biopharma's financial results for FY19 show a worsening net loss and declining sales compared to FY18.
The increase in net loss and decrease in sales are negative indicators for Can-Fite Biopharma's financial health, likely leading to a short-term negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100